ARG’s primary goal is to improve and prolong the lives of the people affected by rare diseases through the clinical trials we manage. We realize our patient-centric approach by carefully cultivating relationships, fostering meaningful communication, and anticipating and addressing all of the challenges in our studies.
ARG knows from experience that the willingness to be flexible has fueled our success in rare disease clinical trials, resulting in approvals with over $3B in sales.
Every patient counts. While large-scale intricately-designed studies can afford to lose patients, clinical trials for rare patient populations are not buffered for atrophy. ARG emphasizes that every patient is vital; in fact, we place the utmost importance on every data point in every study.
ARG’s history of successfully operationalizing rare disease clinical research has been driven by comprehensive engagement with our sponsors.
In a recent engagement survey, 98.6% of employees indicated they believe ARG cares about them, and 97.8% responded that they see themselves working for ARG for many years to come.